Swiss rush to Roche
Roche has done it again. This time, the pharmaceutical company has taken Sfr4bn out of the market in a six month deal at about 68bp over Libor — a low price for a corporate bond, irrespective of the ultra-short maturity. At Sfr4bn this is the biggest single tranche deal on record to hit the Swiss market. Read EuroWeek on Friday to find out the secret of Roche’s success in Swiss francs and whether or not it has created a new benchmark for size.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts